Drug · DIN 02331624
AZARGA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since March 9, 2018; first marketed August 25, 2009.
- Drug Identification Number (DIN)
- 02331624
- Company (DIN owner)
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Suspension
- Route
- Ophthalmic
- Therapeutic class (ATC)
- Timolol, combinations S01ED51
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| BRINZOLAMIDE | 1 % | W/V |
| TIMOLOL (TIMOLOL MALEATE) | 0.5 % | W/V |
Notices of Compliance
Health Canada approvals that name this DIN.
- November 18, 2020: NOC 24643Supplement to a New Drug Submission (SNDS) · To add a new adverse reaction of hallucination to the product monograph, in the post-marketing adverse drug reactions section based on post marketing spontaneous case reports and literature cases
- March 23, 2017: NOC 19090New Drug Submission (NDS) · Transfer of drug identification N umber
- August 13, 2009: NOC 10504New Drug Submission (NDS)